Kenta Biotech Announces Collaboration with Rentschler Biotechnologie GmbH & Co. for Antibody Development Against Hospital-Acquired Infections

Published: Jan 14, 2010

BERNE, Switzerland--(BUSINESS WIRE)--Kenta Biotech today announced an agreement with Rentschler Biotechnologie for the development of a fully human monoclonal antibody against methicillin-resistant Staphylococcus aureus (MRSA).

Back to news